EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Microwave Ablation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Resectable Stage IIB – IIIB Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study

Chun-Quan Liu iD, Kang-Shun Guo, Qi Qin, Liu Yang, Yong Cui, Mu Hu

Thoracic Cancer · 2025

DOI: 10.1111/1759-7714.70136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025. Verfasst von Chun-Quan Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chemotherapy combined with immunotherapy has emerged as a pivotal neoadjuvant strategy for resectable locally advanced non‐small cell lung cancer (NSCLC). However, several problems urge to be resolved, including suboptimal pathologic complete response(pCR)/major pathologic response (MPR). Microwave ablation (MWA) exerts direct tumoricidal effects through thermal coagulation while releasing tumor‐associated antigens to remodel the local immune microenvironment. In patients with advanced NSCLC, MWA combined with chemotherapy or immunotherapy has shown prolonged overall survival (OS).

Methods

This study investigated the neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy for optimizing neoadjuvant treatment strategies of stage IIB–IIIB NSCLC. We evaluated the pCR, MPR, R0 resection rate, and incidence of grade ≥ 3 adverse events in patients following surgical resection, aiming to improve surgical outcomes and survival.

Results

This study confirmed the safety and feasibility of a neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy in patients with NSCLC. The study was a single‐center retrospective analysis ( n = 8), demonstrating a pCR rate of 50%, an MPR rate of 62.5%, an R0 resection rate of 100%, with no increase in grade ≥ 3 adverse events.

Conclusions

In this retrospective analysis, the neoadjuvant therapeutic strategy combining MWA with chemotherapy and immunotherapy preliminarily demonstrates safety and feasibility in resectable stage IIB–IIIB NSCLC, while showing potential to improve pCR and MPR rates. Furthermore, the integration of MWA may propose a novel treatment approach for optimizing neoadjuvant therapy. Prospective multicenter clinical trials are required to further validate the safety and feasibility, as well as its impact on long‐term survival benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoadjuvant TherapyImmunotherapyMicrowavesHumansRetrospective StudiesFemaleMaleMiddle AgedAgedNeoplasm StagingCombined Modality Therapy

Stichwörter der Autor:innen

chemotherapyimmunotherapymicrowave ablationneoadjuvant therapynon‐small cell lung cancerpathological complete response

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Department of Thoracic Surgery, Beijing Chuiyangliu Hospital Affiliated to Tsinghua University, Beijing, China.

ORCID-Profile: Chun-Quan Liu

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Liu, C. Q., Guo, K. S., Qin, Q., Yang, L., Cui, Y., & Hu, M. (2025). Microwave Ablation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Resectable Stage IIB – IIIB Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70136

Vancouver

Liu CQ, Guo KS, Qin Q, Yang L, Cui Y, Hu M. Microwave Ablation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Resectable Stage IIB – IIIB Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study. Thoracic Cancer. 2025. doi:10.1111/1759-7714.70136

BibTeX
@article{Liu2025,
  author = {Liu, Chun-Quan and Guo, Kang-Shun and Qin, Qi and Yang, Liu and Cui, Yong and Hu, Mu},
  title = {Microwave Ablation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Resectable Stage IIB – IIIB Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study},
  journal = {Thoracic Cancer},
  year = {2025},
  doi = {10.1111/1759-7714.70136}
}
Kostenlos starten →